Tempus AI, Inc.
TEMFull coverage—Tempus AI, Inc.
TEMNasdaqFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Tempus AI runs cancer and hereditary genetic testing laboratories and licenses the de-identified data they produce to drug companies, with AI applications still a small part of revenue. In the third quarter of fiscal 2026 revenue grew 23.1% to $411.5 million and the company raised its full-year guidance for the third time, while data revenue from customers not related to the founder grew fast but growth in Insights, the core licensing product, slowed for the third quarter running. The smaller net loss came mainly from gains on shares Tempus holds, and the operating loss, after stock-based compensation of 11.7% of revenue, barely changed. Moatsight estimates revenue of $1,920.3 million over the four quarters to the third quarter of fiscal 2027, including the pending Personalis purchase, and expects GAAP losses to continue over that period.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers